The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest.
The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest.